Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Aug 2;40(4):1863–1874. doi: 10.3892/or.2018.6621

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Gu et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 5. — Silencing of E2F1 leads to changes in cellular behavior of human HCC cells. (A) E2F1 downregulation and MTA treatment significantly reduced cell proliferation as determined by cell proliferation assay. (B) E2F1-silenced HCC cells as well as MTA-treated cells showed decreased migration and invasion through extracellular matrix (ECM) as indicated by Transwell migration assay. Representative images (left) and quantification (right) are shown. The number of cells migrated through the ECM after 24 h was counted in five randomly selected (×200) microscopic fields. (C) E2F1 downregulation and MTA treatment led to reduced cell invasive ability as revealed by wound healing assay. At 24 h, the extent of wound closure was 33.17% (±2.79%) for E2F1-silenced cells, 37.67% (±1.86%) for MTA-treated cells, but was 95.00% (±2.61%) for the control cells (NC) transduced with scrambled-shRNA vectors. Each error bar represents the mean ± SD of three replicate samples. *P<0.05. HCC, hepatocellular carcinoma.